Covid‐19 vaccines and variants of concern: a review
I Hadj Hassine - Reviews in medical virology, 2022 - Wiley Online Library
Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …
A systematic review on COVID-19 vaccine strategies, their effectiveness, and issues
SS Khandker, B Godman, MI Jawad, BA Meghla… - Vaccines, 2021 - mdpi.com
COVID-19 vaccines are indispensable, with the number of cases and mortality still rising,
and currently no medicines are routinely available for reducing morbidity and mortality, apart …
and currently no medicines are routinely available for reducing morbidity and mortality, apart …
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
Delhi, the national capital of India, experienced multiple severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of> …
coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of> …
SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi …
Importance A surge of COVID-19 occurred from March to June 2021, in New Delhi, India,
linked to the B. 1.617. 2 (Delta) variant of SARS-CoV-2. COVID-19 vaccines were rolled out …
linked to the B. 1.617. 2 (Delta) variant of SARS-CoV-2. COVID-19 vaccines were rolled out …
Effectiveness of COVID-19 vaccines against Delta (B. 1.617. 2) variant: a systematic review and meta-analysis of clinical studies
The high transmissibility, mortality, and morbidity rate of the SARS-CoV-2 Delta (B. 1.617. 2)
variant have raised concerns regarding vaccine effectiveness (VE). To address this issue, all …
variant have raised concerns regarding vaccine effectiveness (VE). To address this issue, all …
SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight …
We are currently approaching three years since the beginning of the coronavirus disease
2019 (COVID-19) pandemic. SARS-CoV-2 has caused extensive disruptions in everyday …
2019 (COVID-19) pandemic. SARS-CoV-2 has caused extensive disruptions in everyday …
Efficacy and safety of COVID‐19 vaccines
Cochrane Emergency and Critical Care … - Cochrane Database …, 1996 - cochranelibrary.com
Background Different forms of vaccines have been developed to prevent the SARS‐CoV‐2
virus and subsequent COVID‐19 disease. Several are in widespread use globally …
virus and subsequent COVID‐19 disease. Several are in widespread use globally …
Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross …
AK Singh, SR Phatak, R Singh, K Bhattacharjee… - Diabetes & Metabolic …, 2022 - Elsevier
Background and aims There is limited data available on longitudinal humoral antibody
dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) …
dynamics following two doses of ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) …
COVID-19 vaccine platforms: Challenges and safety contemplations
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a
pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt …
pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt …
Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India
Effectiveness of corona virus disease-19 (COVID-19) vaccines used in India is unexplored
and need to be substantiated. The present case-control study was planned to elicit the …
and need to be substantiated. The present case-control study was planned to elicit the …